LOS ANGELES--(BUSINESS WIRE)--Neural Analytics Inc., a medical device company focused on developing devices and services to measure, diagnose and track brain health, announced today that it has secured $10 MM in Series A financing. This brings the total investment amount in Neural Analytics to $13 MM including their $3 MM Series Seed financing last year.
The latest close includes new investors JSR Limited, a professionally managed venture capital fund, and Taiyu Capital, a subsidiary of TigerMed, a global leading provider of outsourced clinical development services.
“Neural Analytics is very pleased to complete this financing, and we welcome JSR Limited and Taiyu to our multinational syndicate of top tier investors,” said Leo Petrossian, PhD, co-founder and Chief Executive Officer of Neural Analytics. “This remarkable level of interest and significant capitalization demonstrates high confidence in our team and the excitement around the launch of our clinical trials early next year.”
Funds will support clinical trials in 2016 and ongoing development of new products and continuing research studies on Traumatic Brain Injury (TBI) including athletes who play sports with a high risk of concussion. Every year, an estimated 1.7 million people suffer from TBI and another 3.8 million Americans experience a concussion.
About Neural Analytics Inc.
Neural Analytics is creating products and services to measure, diagnose and track brain health with a current focus on Traumatic Brain Injury (TBI). NA combines leading edge data science with medical robotics to empower first responders and clinicians to accurately assess mild to severe TBI, including concussions. NA’s devices are portable, reliable and produce precise and objective physiological measurements.
Further information is available at www.neuralanalytics.com.
